Advertisement

Journal of Nephrology

, Volume 32, Issue 5, pp 719–731 | Cite as

Anticoagulation in CKD and ESRD

  • Kelvin Cheuk-Wai LeungEmail author
  • Jennifer Marie MacRae
Review

Abstract

In this review we discuss the evolving literature of anticoagulation in the context of the nephrology patient. Whereas CKD patients with atrial fibrillation, should be anticoagulated, the benefit of anticoagulation for those on dialysis remains controversial due to an increased risk of bleeding. The availability of direct oral anticoagulants offers new options for those with CKD. Until studies are available in stage 4 and 5/dialysis, this class of medication should be used with caution in this population. For anticoagulated patients requiring interventional procedures, a risk-based approach should be employed to determine those who will benefit from bridging anticoagulation. Either unfractionated heparin or low molecular weight heparin are adequate choices for bridging anticoagulation. Unfractionated heparin and renally dosed low molecular weight heparin can be safely used in non-end stage CKD patients with an acute coronary syndrome. Similarly, the use of unfractionated heparin and low molecular weight heparin are comparable for thromboembolic prophylaxis in CKD/dialysis and extracorporeal circuit anticoagulation of the dialysis circuit.

Keywords

Anticoagulation Hemodialysis CKD Heparin LMWH 

Notes

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there are no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Alonso A, Lopez FL, Matsushita K et al (2011) Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 123:2946–2953.  https://doi.org/10.1161/CIRCULATIONAHA.111.020982 Google Scholar
  2. 2.
    Ananthapanyasut W, Napan S, Rudolph EH et al (2010) Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 5:173–181.  https://doi.org/10.2215/CJN.03170509 Google Scholar
  3. 3.
    Winkelmayer WC, Patrick AR, Liu J et al (2011) The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22:349–357.  https://doi.org/10.1681/ASN.2010050459 Google Scholar
  4. 4.
    Genovesi S, Pogliani D, Faini A et al (2005) Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 46:897–902.  https://doi.org/10.1053/j.ajkd.2005.07.044 Google Scholar
  5. 5.
    Genovesi S, Vincenti A, Rossi E et al (2008) Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 51:255–262.  https://doi.org/10.1053/j.ajkd.2007.10.034 Google Scholar
  6. 6.
    Reinecke H, Brand E, Mesters R et al (2009) Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 20:705–711.  https://doi.org/10.1681/ASN.2007111207 Google Scholar
  7. 7.
    O’Neal WT, Tanner RM, Efird JT et al (2015) Atrial fibrillation and incident end-stage renal disease: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Int J Cardiol 185:219–223.  https://doi.org/10.1016/j.ijcard.2015.03.104 Google Scholar
  8. 8.
    Bansal N, Fan D, Hsu C, -y. et al (2013) Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127:569–574.  https://doi.org/10.1161/CIRCULATIONAHA.112.123992 Google Scholar
  9. 9.
    Nakayama M, Metoki H, Terawaki H et al (2018) Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. Nephrol Dial Transpl.  https://doi.org/10.1093/ndt/gfm051 Google Scholar
  10. 10.
    Olesen JB, Lip GYH, Kamper A-L et al (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635.  https://doi.org/10.1056/NEJMoa1105594 Google Scholar
  11. 11.
    Masson P, Webster AC, Hong M et al (2015) Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transpl 30:1162–1169.  https://doi.org/10.1093/ndt/gfv009 Google Scholar
  12. 12.
    Go AS, Fang MC, Udaltsova N et al (2009) Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119:1363–1369.  https://doi.org/10.1161/CIRCULATIONAHA.108.816082 Google Scholar
  13. 13.
    Nelson SE, Shroff GR, Li S, Herzog CA (2012) Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients. J Am Heart Assoc 1:e002097.  https://doi.org/10.1161/JAHA.112.002097 Google Scholar
  14. 14.
    Vázquez E, Sánchez-Perales C, Lozano C et al (2003) Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 92:868–871.  https://doi.org/10.1016/S0002-9149(03)00904-4 Google Scholar
  15. 15.
    U.S. Renal Data System (2012) USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MDGoogle Scholar
  16. 16.
    Mcnamara RL, Tamariz LJ, Segal JB, Bass EB (2003) Clinical guidelines management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 139:1018–1033Google Scholar
  17. 17.
    Friberg L, Rosenqvist M, Lip GYH (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the swedish atrial fibrillation cohort study. Circulation 125:2298–2307.  https://doi.org/10.1161/CIRCULATIONAHA.111.055079 Google Scholar
  18. 18.
    Macle L, Cairns J, Leblanc K et al (2016) 2016 focused update of the canadian cardiovascular society guidelines for the management of atrial fibrillation. Can J Cardiol 32:1170–1185.  https://doi.org/10.1016/j.cjca.2016.07.591 Google Scholar
  19. 19.
    Ravera M, Bussalino E, Paoletti E et al (2019) Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: do we need a novel risk score calculator? Int J Cardiol 274:179–185.  https://doi.org/10.1016/j.ijcard.2018.07.066 Google Scholar
  20. 20.
    Dahal K, Kunwar S, Rijal J et al (2016) Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 149:951–959.  https://doi.org/10.1378/chest.15-1719 Google Scholar
  21. 21.
    Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992.  https://doi.org/10.1056/NEJMoa1107039 Google Scholar
  22. 22.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151.  https://doi.org/10.1056/NEJMoa0905561 Google Scholar
  23. 23.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.  https://doi.org/10.1056/NEJMoa1009638 Google Scholar
  24. 24.
    Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104.  https://doi.org/10.1056/NEJMoa1310907 Google Scholar
  25. 25.
    Turakhia MP, Blankestijn PJ, Carrero J-J et al (2018) Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J.  https://doi.org/10.1093/eurheartj/ehy060 Google Scholar
  26. 26.
    Keskar V, Sood MM (2016) Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: con. Clin J Am Soc Nephrol 11:2085–2092.  https://doi.org/10.2215/CJN.03200316 Google Scholar
  27. 27.
    McCullough PA, Ball T, Cox KM, Assar MD (2016) Use of oral anticoagulation in the management of atrial fibrillation in patients with ESRD: pro. Clin J Am Soc Nephrol 11:2079–2084.  https://doi.org/10.2215/CJN.02680316 Google Scholar
  28. 28.
    Bansal N (2016) Use of oral anticoagulation for patients with ESRD on hemodialysis with atrial fibrillation: verdict 1. Clin J Am Soc Nephrol 11:2093–2094.  https://doi.org/10.2215/CJN.08610816 Google Scholar
  29. 29.
    Ashley J, Sood MM (2018) Novel oral anticoagulants in chronic kidney disease. Curr Opin Nephrol Hypertens.  https://doi.org/10.1097/MNH.0000000000000410 Google Scholar
  30. 30.
    Hart RG, Eikelboom JW, Brimble KS et al (2013) Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 29:S71–S78.  https://doi.org/10.1016/j.cjca.2013.04.005 Google Scholar
  31. 31.
    Fanikos J, Burnett AE, Mahan CE, Dobesh PP (2017) Renal function considerations for stroke prevention in atrial fibrillation. Am J Med 130:1015–1023.  https://doi.org/10.1016/j.amjmed.2017.04.015 Google Scholar
  32. 32.
    Sciascia S, Radin M, Schreiber K et al (2017) Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents. Intern Emerg Med 12:1101–1108.  https://doi.org/10.1007/s11739-017-1753-2 Google Scholar
  33. 33.
    Steffel J, Verhamme P, Potpara TS et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393.  https://doi.org/10.1093/eurheartj/ehy136 Google Scholar
  34. 34.
    Van Der Meersch H, De Bacquer D, De Vriese AS (2017) Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis. Am Heart J 184:37–46.  https://doi.org/10.1016/j.ahj.2016.09.016 Google Scholar
  35. 35.
    Winkelmayer WC, Liu J, Patrick AR et al (2013) Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis. J Nephrol 25:341–353.  https://doi.org/10.5301/jn.5000010 Google Scholar
  36. 36.
    Kai B, Bogorad Y, Nguyen LAN et al (2017) Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Hear Rhythm 14:645–651.  https://doi.org/10.1016/j.hrthm.2017.01.047 Google Scholar
  37. 37.
    Shen JI, Montez-Rath ME, Lenihan CR et al (2015) Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66:677–688.  https://doi.org/10.1053/j.ajkd.2015.05.019 Google Scholar
  38. 38.
    Bonde AN, Lip GYH, Kamper AL et al (2014) Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64:2471–2482.  https://doi.org/10.1016/j.jacc.2014.09.051 Google Scholar
  39. 39.
    Voskamp PWM, Rookmaaker MB, Verhaar MC et al (2018) Vitamin K antagonist use and mortality in dialysis patients. Nephrol Dial Transpl 33:170–176.  https://doi.org/10.1093/ndt/gfx199 Google Scholar
  40. 40.
    National Kidney Foundation (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:S1–S153Google Scholar
  41. 41.
    Herzog CA, Asinger RW, Berger AK et al (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 80:572–586.  https://doi.org/10.1038/ki.2011.223 Google Scholar
  42. 42.
    Thomson BKA, MacRae JM, Barnieh L et al (2011) Evaluation of an electronic warfarin nomogram for anticoagulation of hemodialysis patients. BMC Nephrol 12:46.  https://doi.org/10.1186/1471-2369-12-46 Google Scholar
  43. 43.
    Sood MM, Rigatto C, Bueti J et al (2009) Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transpl 24:3162–3167.  https://doi.org/10.1093/ndt/gfp252 Google Scholar
  44. 44.
    Chan KE, Edelman ER, Wenger JB et al (2015) Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131:972–979.  https://doi.org/10.1161/CIRCULATIONAHA.114.014113 Google Scholar
  45. 45.
    Siontis KC, Zhang X, Eckard A et al (2018) Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 138:1519–1529.  https://doi.org/10.1161/CIRCULATIONAHA.118.035418 Google Scholar
  46. 46.
    Pollack CV, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520.  https://doi.org/10.1056/NEJMoa1502000 Google Scholar
  47. 47.
    Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424.  https://doi.org/10.1056/NEJMoa1510991 Google Scholar
  48. 48.
    Reed D, Palkimas S, Hockman R et al (2018) Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2:291–298.  https://doi.org/10.1002/rth2.12083 Google Scholar
  49. 49.
    Dias C, Moore KT, Murphy J et al (2016) Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 43:229–236.  https://doi.org/10.1159/000445328 Google Scholar
  50. 50.
    Mavrakanas TA, Samer CF, Nessim SJ et al (2017) Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 28:2241–2248.  https://doi.org/10.1681/ASN.2016090980 Google Scholar
  51. 51.
    Wang X, Tirucherai G, Marbury TC et al (2016) Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 56:628–636.  https://doi.org/10.1002/jcph.628 Google Scholar
  52. 52.
    De Vriese AS, Caluwé R, Bailleul E et al (2015) Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 66:91–98.  https://doi.org/10.1053/j.ajkd.2015.01.022 Google Scholar
  53. 53.
    Weenig RH, Sewell LD, Davis MDP et al (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579.  https://doi.org/10.1016/j.jaad.2006.08.065 Google Scholar
  54. 54.
    Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3:1139–1143.  https://doi.org/10.2215/CJN.00530108 Google Scholar
  55. 55.
    Mazhar a R, Johnson RJ, Gillen D et al (2001) Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324–332.  https://doi.org/10.1046/j.1523-1755.2001.00803.x Google Scholar
  56. 56.
    Garza-Mayers AC, Shah R, Sykes DB et al (2018) The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis. Am J Nephrol 48:168–171.  https://doi.org/10.1159/000491881 Google Scholar
  57. 57.
    Rattazzi M, Faggin E, Bertacco E et al (2018) Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE-/- mice. Cardiovasc Ther 36:e12438.  https://doi.org/10.1111/1755-5922.12438 Google Scholar
  58. 58.
    Douketis JD, Spyropoulos AC, Kaatz S et al (2015) Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373:823–833.  https://doi.org/10.1056/NEJMoa1501035 Google Scholar
  59. 59.
    Tseng E, Crowther MA, Hillis CM (2015) Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation. CMAJ 188:361–362.  https://doi.org/10.1503/cmaj.150867 Google Scholar
  60. 60.
    Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e326S–e350S.  https://doi.org/10.1378/chest.11-2298 Google Scholar
  61. 61.
    January CT, Wann LS, Alpert JS et al (2016) AHA/ACC/HRS Practice Guideline 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SoGoogle Scholar
  62. 62.
    Davenport A (2009) Review article: low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. Nephrology 14:455–461.  https://doi.org/10.1111/j.1440-1797.2009.01135.x Google Scholar
  63. 63.
    Shen JI, Winkelmayer WC (2012) Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis 60:473–486.  https://doi.org/10.1053/j.ajkd.2012.03.017 Google Scholar
  64. 64.
    Johansen KB, Balchen T (2013) Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance ? 2:1.  https://doi.org/10.1186/2162-3619-2-21
  65. 65.
    Merli GJ, Groce JB (2010) Pharmacological and clinical differences between low-molecular-weight heparins implications for prescribing practice and therapeutic interchange. Pharm Ther 35:95–105Google Scholar
  66. 66.
    Lim W, Francesco D, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:Abstract.  https://doi.org/10.7326/0003-4819-144-9-200605020-00011 Google Scholar
  67. 67.
    Becker RC, Spencer FA, Gibson M et al (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753–759.  https://doi.org/10.1067/mhj.2002.120774 Google Scholar
  68. 68.
    Chow SL, Zammit K, West K et al (2003) Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 43:586–590.  https://doi.org/10.1177/0091270003253420 Google Scholar
  69. 69.
    Guillet B, Simon N, Sampol JJ et al (2003) Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 18:2348–2353Google Scholar
  70. 70.
    Lim W, Cook DJ, Crowther M (2004) Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 15:3192–3206.  https://doi.org/10.1097/01.ASN.0000145014.80714.35 Google Scholar
  71. 71.
    Boneu B, Caranobe C, Sie P (1990) Pharmacokinetics of heparin and low molecular weight heparin. Baillieres Clin Haematol 3:531–544Google Scholar
  72. 72.
    Lim W, Dentali F, Eikelboom JW, Crowther MA (2014) Annals of internal medicine review meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673–684Google Scholar
  73. 73.
    Pautas E, Gouin I, Bellot O et al (2002) Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 25:725–733Google Scholar
  74. 74.
    Siguret V, Pautas E, Février M et al (2000) Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 84:800–804Google Scholar
  75. 75.
    Shprecher AR, Cheng-Lai A, Madsen EM et al (2005) Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 25:817–822Google Scholar
  76. 76.
    Kearon C, Ginsberg JS, Julian JA et al (2006) Comparison of fixed-dose weight-adjusted weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942.  https://doi.org/10.1001/jama.296.8.935 Google Scholar
  77. 77.
    Leizorovicz A, Siguret V, Mottier D (2011) Safety pro fi le of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in renal insufficiency study (IRIS) ☆. Thromb Res 128:27–34.  https://doi.org/10.1016/j.thromres.2011.03.002 Google Scholar
  78. 78.
    Metzger NL, Chesson MM (2010) Thromboembolism in end-stage renal disease. Semin Dial 44:2023–2027Google Scholar
  79. 79.
    Rodger MA, Ramsay T, Mackinnon M et al (2016) Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial. YAJKD 60:427–434.  https://doi.org/10.1053/j.ajkd.2012.01.020 Google Scholar
  80. 80.
    Lim W, Crowther M, Wang L et al (2016) Serial trough anti-Xa levels to assess low molecular weight heparin accumulation in patients with chronic kidney disease: analysis of Crcl < 30 Ml/Min from the trivet study. Am Soc Hematol 128:90Google Scholar
  81. 81.
    Gilchrist IC, Berkowitz SD, Thompson TD et al (2002) Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global use of strategies to open occluded coronary arteries. Am Heart J 144:73–80.  https://doi.org/10.1067/mhj.2002.123112 Google Scholar
  82. 82.
    Basra SS, Tsai P, Lakkis NM (2011) Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol 58:2263–2269.  https://doi.org/10.1016/j.jacc.2011.08.051 Google Scholar
  83. 83.
    Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Socie. Eur Heart J 39:119–177.  https://doi.org/10.1093/eurheartj/ehx393 Google Scholar
  84. 84.
    Roffi M, Patrono C, Collet JP et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of. Eur Heart J 37:267–315.  https://doi.org/10.1093/eurheartj/ehv320 Google Scholar
  85. 85.
    Amsterdam EA, Wenger NK, Brindis RG et al (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary. Circulation 130:2354–2394.  https://doi.org/10.1161/CIR.0000000000000133 Google Scholar
  86. 86.
    Charytan D, Kuntz RE (2006) The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int 70:2021–2030.  https://doi.org/10.1038/sj.ki.5001934 Google Scholar
  87. 87.
    Szummer K, Lundman P, Jacobson SH et al (2010) Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 268:40–49.  https://doi.org/10.1111/j.1365-2796.2009.02204.x Google Scholar
  88. 88.
    Mezzano D, Tagle R, Panes O et al (1996) Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost 76:312–321Google Scholar
  89. 89.
    Fox KAA, Antman EM, Montalescot G et al (2007) The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2249–2255.  https://doi.org/10.1016/j.jacc.2006.12.049 Google Scholar
  90. 90.
    Lim W, Al Saleh K, Douketis JD (2006) Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency. Thromb Res 118:409–416.  https://doi.org/10.1016/j.thromres.2005.03.028 Google Scholar
  91. 91.
    Zeng X, Lincoff AM, Schulz-Schüpke S et al (2018) Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: meta-analysis. J Cardiol 71:494–504.  https://doi.org/10.1016/j.jjcc.2017.10.018 Google Scholar
  92. 92.
    Capodanno D, Gargiulo G, Capranzano P et al (2016) Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: an updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care 5:253–262.  https://doi.org/10.1177/2048872615572599 Google Scholar
  93. 93.
    Guyatt GH, Akl EA, Crowther M et al (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:7S–47S.  https://doi.org/10.1378/chest.1412S3 Google Scholar
  94. 94.
    Pai M, Adhikari NKJ, Ostermann M et al (2018) Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: a subgroup analysis of the PROTECT trial. PLoS One 13:1–15.  https://doi.org/10.1371/journal.pone.0198285 Google Scholar
  95. 95.
    Green MS, Tellor KB, Buckallew AR (2017) Safety and efficacy of enoxaparin compared with unfractionated heparin for venous thromboembolism prophylaxis in hemodialysis patients. Hosp Pharm 52:623–627.  https://doi.org/10.1177/0018578717724799 Google Scholar
  96. 96.
    Mahé I, Aghassarian M, Drouet L et al (2007) Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 97:581–586Google Scholar
  97. 97.
    Cameron JS (2000) Practical haemodialysis began with cellophane and heparin: the crucial role of William Thalhimer (1884–1961). Nephrol Dial Transpl 15:1086–1091Google Scholar
  98. 98.
    Fellner SK, Purkerson ML (2002) Gordon Murray: heparin, hemodialysis and hubris. Am J Nephrol 22:271–277.  https://doi.org/10.1159/000063773 Google Scholar
  99. 99.
    Cronin RE, Reilly RF (2011) Unfractionated heparin for hemodialysis: still the best option. Semin Dial 23:510–515.  https://doi.org/10.1111/j.1525-139X.2010.00770.x Google Scholar
  100. 100.
    Hutchison C, Dasgupta I (2007) National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transpl 22:1680–1684.  https://doi.org/10.1093/ndt/gfm055 Google Scholar
  101. 101.
    Yamamoto S, Koide M, Matsuo M et al (1996) Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 28:82–85.  https://doi.org/10.1016/S0272-6386(96)90134-1 Google Scholar
  102. 102.
    Chang JJY, Parikh CR When heparin causes thrombosis: significance, recognition, and management of heparin-induced thrombocytopenia in dialysis patients. Semin Dial 19:297–304.  https://doi.org/10.1111/j.1525-139X.2006.00176.x
  103. 103.
    Hottelart C, Achard JM, Moriniere P et al (1998) Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs 22:614–617Google Scholar
  104. 104.
    Wasse H, Gillen DL, Ball AM et al (2003) Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 64:1455–1461.  https://doi.org/10.1046/j.1523-1755.2003.00225.x Google Scholar
  105. 105.
    Chachati A, Godon JP (1987) Effect of haemodialysis on upper gastrointestinal tract pathology in patients with chronic renal failure. Nephrol Dial Transpl 1:233–237Google Scholar
  106. 106.
    Yang J-Y, Lee T-C, Montez-Rath ME et al (2012) Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol 23:495–506.  https://doi.org/10.1681/ASN.2011070658 Google Scholar
  107. 107.
    Näsström B, Olivecrona G, Olivecrona T, Stegmayr BG (2003) Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Investig 63:45–54.  https://doi.org/10.1080/00365510310000484 Google Scholar
  108. 108.
    Lai KN, Ho K, Cheung RC et al (2001) Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs 24:447–455Google Scholar
  109. 109.
    Brunelli SM, Cohen DE, Marlowe G et al (2019) Safety and efficacy of heparin during dialysis in the context of systemic anticoagulant and antiplatelet medications. J Nephrol 2019:1–8.  https://doi.org/10.1007/s40620-018-00576-w Google Scholar
  110. 110.
    Al-Saran KA, Sabry A, Taha M et al (2010) Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis. Saudi J Kidney Dis Transpl 21:43–49Google Scholar
  111. 111.
    Lord H, Jean N, Dumont M et al Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 22:58–66.  https://doi.org/10.1159/000046675
  112. 112.
    Blog AJKD (2016) AJKD blog official blog of the american journal of kidney diseases # KidneyWk 2016: the poster sessions late breaking trials and the # NephJC poster tour. https://ajkdblog.org/2016/11/20/kidneywk-2016-the-poster-sessions/. Accessed 9 Sep 2018
  113. 113.
    Soroka S, Agharazii M, Donnelly S et al (2018) An adjustable dalteparin sodium dose regimen for the prevention of clotting in the extracorporeal circuit in hemodialysis: a clinical trial of safety and efficacy (the PARROT study). Can J Kidney Health Dis 5:2054358118809104.  https://doi.org/10.1177/2054358118809104 Google Scholar
  114. 114.
    Kessler M, Moureau F, Nguyen P (2015) Anticoagulation in chronic hemodialysis: progress toward an optimal approach. Semin Dial 28:474–489.  https://doi.org/10.1111/sdi.12380 Google Scholar
  115. 115.
    Mactier R, Hoenich N, Breen C (2011) Renal association clinical practice guideline on haemodialysis. Nephron Clin Pract 118:241–286.  https://doi.org/10.1159/000328072 Google Scholar
  116. 116.
    Golper TA, Fissell R, Fissell WH et al (2014) Hemodialysis: core curriculum 2014. Am J Kidney Dis 63:153–163.  https://doi.org/10.1053/j.ajkd.2013.07.028 Google Scholar
  117. 117.
    Ikizler TA, Schulman G (2005) Hemodialysis: techniques and prescription. Am J Kidney Dis 46:976–981.  https://doi.org/10.1053/j.ajkd.2005.07.037 Google Scholar
  118. 118.
    European Best Practice Guidelines Expert Group on Hemodialysis ERA (2002) Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transpl 17(Suppl 7):63–71.  https://doi.org/10.1093/ndt/17.suppl_7.63 Google Scholar
  119. 119.
    Leo Pharma Inc (2016) Innohep product monograph. http://www.leo-pharma.ca/Files/Filer/LEO_local_downloads/LEO-Pharma.ca/innohep PM (7.0)-23-MAR-2016.pdf. Accessed 9 Sep 2018
  120. 120.
    Kirwan CJ, Baig ZF, Platton S et al (2013) Anti-xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis. Nephron Clin Pract 123:7–12.  https://doi.org/10.1159/000351047 Google Scholar
  121. 121.
    Baglin T, Barrowcliffe TW, Cohen A, Greaves M (2006) Guidelines on the use and monitoring of heparin. Br J Haematol 133:19–34.  https://doi.org/10.1111/j.1365-2141.2005.05953.x Google Scholar
  122. 122.
    Sagedal S, Hartmann A, Sundstrøm K et al (1999) A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transpl 14:1943–1947Google Scholar
  123. 123.
    Polkinghorne KR, Mcmahon LP, Becker GJ (2002) Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 40:990–995.  https://doi.org/10.1053/ajkd.2002.36331 Google Scholar
  124. 124.
    Pfizer Canada (2017) Fragmin product monograph. https://www.pfizer.ca/sites/g/files/g10050796/f/201810/FRAGMIN_PM_E_210778_18Oct2018.pdf. Accessed 25 Jan 2019
  125. 125.
    Saltissi D, Morgan C, Westhuyzen J, Healy H (1999) Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transpl 14:2698–2703.  https://doi.org/10.1093/ndt/14.11.2698 Google Scholar
  126. 126.
    anofi-aventis Canada (2017) Lovenox & Lovenox HP (enoxaparin sodium) product monograph. http://products.sanofi.ca/en/lovenox.pdf. Accessed 25 Jan 2019
  127. 127.
    Hainer JW, Sherrard DJ, Swan SK et al (2002) Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 40:531–538.  https://doi.org/10.1053/ajkd.2002.34911 Google Scholar
  128. 128.
    Hoy SM, Scott LJ, Plosker GL (2010) Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs 70:1319–1347.  https://doi.org/10.2165/11203710-000000000-00000 Google Scholar
  129. 129.
    Daugirdas J, Blake P, Ing T (2015) Handbook of dialysis, fifth. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar

Copyright information

© Italian Society of Nephrology 2019

Authors and Affiliations

  1. 1.MedicineUniversity of CalgaryCalgaryCanada
  2. 2.Department of Cardiac SciencesUniversity of CalgaryCalgaryCanada
  3. 3.Foothills Medical CentreCalgaryCanada

Personalised recommendations